Industry

nChroma Bio Abstracts Accepted for The Liver Meeting® 2025 of the American Association for the Study of Liver Diseases (AASLD)

BOSTON–(BUSINESS WIRE)–#AASLD–nChroma Bio (“nChroma”), a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced the acceptance of three abstracts, including a poster of distinction, at the upcoming AASLD Liver Meeting®, taking place November 7 to 11, 2025, in Washington, D.C. “At AASLD, we’re showcasing the … [Read more…]

New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies

First evaluation of benefit-to-burden for new screening options using methodologies adopted by the United States Preventive Services Task Force Noninvasive test performance is critical to support patient outcomes and reduce burden on limited colonoscopy capacity MADISON, Wis.–(BUSINESS WIRE)–Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests today announced the publication … [Read more…]

RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older

TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has conducted a Phase 2 clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (ages 5-14) with achondroplasia (ACH). The company announced today that the administration of the high-dose (0.6 mg/kg) subcutaneous injection (once biweekly) group (Cohort 2 Note 1) has completed … [Read more…]

Children’s Hospital Los Angeles Recognized Among the United States’ Top 10 Children’s Hospitals for 17 Consecutive Years

U.S. News Honor Roll of Best Children’s Hospitals distinguishes CHLA with six specialties ranking in top 10 in the nation LOS ANGELES–(BUSINESS WIRE)–As a leader in pediatric academic medicine for nearly 125 years, Children’s Hospital Los Angeles (CHLA) continues to fulfill its mission by advancing care and making discoveries that enhance and save lives. Today, … [Read more…]

Stability Testing of Pharmaceuticals and Biopharmaceuticals Training Course: Requirements for New and Existing Drug Substances, Products and Line Extensions (Nov 10th – Nov 11th, 2025) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Stability Testing of Pharmaceuticals and Biopharmaceuticals Training Course (Nov 10th – Nov 11th, 2025)” training has been added to ResearchAndMarkets.com’s offering. By attending this intensive two-day seminar, delegates will learn how to: Carry out appropriate stability studies and manage stability samples and facilities Design stability studies that are suitable for global marketing Increase … [Read more…]

KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe

Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked to injectable therapies FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary … [Read more…]

Kerecis to Showcase Medical Fish Skin for Reconstructive Surgery at Plastic Surgery The Meeting 2025

Company highlights innovative biologic solutions and hosts Taste of Iceland event featuring a keynote on soft-tissue repair NEW ORLEANS–(BUSINESS WIRE)–#kerecis–Kerecis, the company pioneering the use of sustainably sourced fish skin in cellular therapy and tissue regeneration, will present its expanding portfolio of fish-skin grafts at Plastic Surgery The Meeting (“PSTM”) 2025, taking place October 9–12 … [Read more…]

GoodRx Expands Affordable Access to Repatha® with Nearly 60% Savings

The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy SANTA MONICA, Calif.–(BUSINESS WIRE)–GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to … [Read more…]

OneMedNet Selects Palantir to Advance Healthcare AI and Data Analytics

DENVER & MINNEAPOLIS–(BUSINESS WIRE)–OneMedNet Corporation (Nasdaq: ONMD) has selected Palantir Technologies (Nasdaq: PLTR) to transform the healthcare AI and Real-World Data (RWD) analytics marketplace. Palantir’s Artificial Intelligence Platform will provide the infrastructure for OneMedNet’s iRWD™ near real-time AI powered provider network (“network”) enabling OneMedNet to empower life sciences, medical device, and research organizations with anonymized, … [Read more…]

DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02

Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only therapy to significantly improve overall survival versus chemotherapy in this patient population DATROWAY also demonstrated a highly statistically significant and clinically meaningful improvement in the dual primary endpoint of progression-free survival Plans for global regulatory submissions are underway TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Positive topline … [Read more…]